establish an early indicator of therapeutic efficacy, and several studies are using the undetectable PSA rate after a short course of therapy after 12 or 24 months with and without the recovery of testosterone in this fashion. The ongoing Abicure trial (NCT01751451), for example, would benefit from an analysis demonstrating that their primary endpoint of undetectable PSA with a recovered testosterone level of >150 ng/dL at 18 months is clinically meaningful.
To reliably evaluate whether these novel agents are effective before developing evidence of metastasis using undetectable PSA as an early endpoint, it is necessary to establish the rate at which patients have durable responses after ADT is discontinued. Furthermore, identifying baseline clinical characteristics associated with durable response may help to identify patient populations with more versus less aggressive disease and help inform appropriate therapy and clinical trial eligibility. Finally, it is informative to empirically assess whether durable response is associated with long-term outcomes, including metastasis, prostate cancer-specific death, and death from any causes. These are the three goals of this study.
| METHODS

| Patients
This is a single-center retrospective study of men with nonmetastatic prostate cancer who received a short course of ADT for BCR. The medical records for this analysis were abstracted from the Caisis database from March 1986 to September 2017, an in-house repository that stores the patient medical information for all genitourinary cancer patients seen at the University of Washington Medical Center and Seattle Cancer Care Alliance. To determine the patients eligible for this analysis, the Caisis database was queried for patients with a histological diagnosis of prostate cancer with any T and N stage without metastasis (M0) from bone and computed tomography scans.
The search query was then narrowed to those who underwent radical prostatectomy for localized disease as primary treatment. Finally, patients who underwent 6-12 months of subsequent short-term ADT were included. Baseline characteristics, laboratory, pathology, treatment, and outcome data were collected and compiled. The study was reviewed and approved by the institutional review board of the Fred Hutchinson Cancer Consortium.
Patients who received adjuvant therapy after surgery were included in this analysis with or without simultaneous ADT. For patients who received ADT with radiation therapy concurrently, the following cycle of ADT, which was the first cycle of ADT with non-curative intent, was used in this analysis only if testosterone had recovered to ≥50 ng/dL. Similarly, patients were considered eligible for this analysis if they previously received ADT prior to surgery and testosterone was proven to have recovered to ≥50 ng/dL at the time of ADT initiation with non-curative intent. Following surgery or adjuvant therapy, patients must have had BCR, defined as PSA ≥0.2 ng/mL on a lab draw and >0.2 ng/mL on the following lab draw, with at least 1 month between obtained values. 13 Time to recovery of testosterone to non-castrate levels during the off cycle was also abstracted and defined separately for separate analyses as testosterone ≥50 ng/dL and ≥150 ng/dL. Patients were then evaluated for PSA recurrence following completion of short-term ADT using the same definition as for initial BCR.
| Study design
Our primary aim was to determine the proportion of men with undetectable PSA 12 and 24 months after short-term ADT for BCR.
Proportions were calculated with and without conditioning on testosterone recovery to non-castrate levels (≥50 ng/dL and ≥150 ng/dL).
A secondary aim of this study was to evaluate associations between PSA status at these times and demographic and clinicopathologic characteristics, namely patient age and PSA at diagnosis, grade group, time from prostatectomy to BCR, and PSA doubling time.
PSA doubling time from BCR to initiation of ADT was calculated using all values from BCR after last local definitive therapy to the initiation of ADT using the Memorial Sloan Kettering prostate cancer nomogram.
14 Definitive local therapy included primary, adjuvant, or salvage radiation therapy or surgery.
The final aim of this study was to determine associations between PSA status and long-term outcomes, namely metastasis-free survival, prostate-cancer specific death, and death from any cause. Date of metastasis was defined by RECIST 1.1 criteria with any lymph nodes >1.5 cm on the short axis, nodules >1 cm on the long axis, or new skeletal metastasis identified by bone or computed tomography scans. 15 
| Statistical methods
To test whether proportions of men with undetectable PSA 12 and 24 months after completing ADT for BCR exceeded a nominal level, exact binomial tests were used to determine whether the true proportion was equal to 5%. The test was repeated among subgroups of men who recovered testosterone to non-castrate levels of ≥50 ng/dL and ≥150 ng/dL. To evaluate associations between PSA status and baseline characteristics, logistic regressions were fit using complete case analyses. To evaluate associations between PSA status and long-term outcomes, Kaplan-Meier estimation, and log-rank tests (with competing risks censored) were used. To explore whether associations remained after accounting for any significant baseline characteristics variables, Cox proportional hazards regressions were fit and likelihood ratio tests were used in complete case analyses.
| RESULTS
From the initial Caisis query, 190 men were evaluated under study criteria. After data abstraction, 93 men met the eligibility criteria for this analysis ( Figure 1 ). Characteristics of the eligible patients are presented in Table 1 . At diagnosis, the median age was 60 years (range, 44-76 years) with a median PSA of 8. Of the 93 eligible patients who received ADT after radical prostatectomy, 23/93 (25%; P < 0.001) of men had undetectable PSA at 12 months and 14/93 (15%; P < 0.001) of men had undetectable PSA at 24 months (Table 2) . Among men who recovered testosterone to ≥50 ng/dL, 13/65 (20%; P < 0.001) had undetectable PSA at 12 months and 10/65 (15%; P = 0.001) had undetectable PSA at 24 months. For men who recovered testosterone to ≥150 ng/dL, 13/60 (22%; P < 0.001) had undetectable PSA at 12 months and 10/60 (17%; P < 0.001) had undetectable PSA at 24 months.
Results of the logistic regression to evaluate associations between PSA status and baseline characteristics are presented in Table 3 . There was a significant association between age at diagnosis and undetectable PSA at 12 months (P = 0.006). Specifically, being 1 year older at diagnosis was associated with a 14% (95%CI 5-24%; 17 A demonstrated increase in PSAdt even with the lack of active treatment weakens the clinical utility of this endpoint in trials without a placebo arm.
Furthermore, it has been shown that patients who receive ADT have altered PSAdt when testosterone and PSA are rising concomitantly. 18 As a result, we restricted our analysis to include PSAdt only as a baseline prognostic marker and did not evaluate correlation between PSAdt after initial ADT and testosterone recovery with metastasis-free survival or overall survival.
As demonstrated by the CHAARTED, STAMPEDE, and LATITUDE trials, there is a proven benefit to more aggressive systemic treatment earlier in the disease course for men with metastatic prostate cancer.
Moving efficacious agents earlier in the disease course is currently being explored and greatly increases the need for a reliable clinical trial endpoint. In addition, staging and identification of oligometastatic prostate cancer is improving with next generation imaging, such as 18F-fluciclovine (FACBC) and prostate-specific membrane antigen (PSMA) positron emission tomography scans. These imaging modalities are uncovering previously undetected disease, leading to many metastasis-directed therapies of uncertain benefit. Hence, this new field would also benefit from an early endpoint, such as time to PSA progression. 19 Thus, as research protocols continue to explore treatment intensification for both BCR and oligometastatic disease states, undetectable PSA at a pre-specified landmark may prove to be an effective marker with a wide breadth of applications if correlations with long-term outcomes can be confirmed in other patient populations.
Designing effective clinical trials relies on identifying the men who may benefit most from novel and experimental therapies. Our multivariate analysis indicates that being older at diagnosis is protective of PSA progression within 12 months. Although it could be suggested that the significant rate of undetectable PSA could be attributed to an older age and thus longer duration of undetectable PSA or time to testosterone recovery, the median age at diagnosis for the cohort of men in this study was only 60 years. The remainder of the known prognostic predictor variables, including PSA doubling time,
were not significantly associated with PSA status at 12 months. Thus, this analysis was unable to determine which patients were more likely to respond favorably to ADT beyond the trend for patients with advanced age. This suggests that PSA status may provide independent clinical information.
The patients in this study could not be said to have indolent prostate cancer, so that cannot explain the unexpectedly high proportions with undetectable PSA at 12 or 24 months. For example, median PSA doubling time of this cohort was 6 months, highlighting that this was a patient population with relatively aggressive disease biology (Table 1) . 20 Median time to BCR in the population was less than 2 years, which is also indicative of men with more aggressive prostate cancer. 21 So, although the proportion of men with undetectable PSA at 12 months indicated in this analysis is greater than previously expected, it is unlikely due to patient selection of an indolent cohort of patients that did not require therapy. Limitations to this analysis include the sample size, especially in the evaluation of association between PSA status and baseline characteristics.
The single-institution data source and limited number of providers warrants independent confirmation in other patient populations. Also, PSAdt was unable to be calculated for men without three PSA values and these men may be more likely to have detectable PSA at 12 months due to shorter follow up, introducing possible bias to this measure. Finally, as in all retrospective analyses, this study is subject to possible confounding and other biases.
| CONCLUSIONS
In this single-institution study, a significant proportion of biochemically-recurrent prostate cancer patients had undetectable PSA after short course ADT at 12 or 24 months. Undetectable PSA at 12 or 24 months was associated with risks of metastasis and death. Hence, PSA status at one of these landmarks may be further evaluated as an early endpoint for use in clinical trials. Additional analyses should be performed in larger, multi-institutional data sets to confirm the clinical value of this endpoint.
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FIGURE 3 A, Kaplan-Meier curves for cancer-specific survival stratified by detectable PSA at 12 months (n = 86). B, Kaplan-Meier curves for overall survival stratified by detectable PSA at 12 months (n = 86)
